Lu-177 DOTATATE + Cabozantanib in NETs

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

CLINICALTRIALS.GOV IDENTIFIER: NCT05249114

DRUG/TREATMENT: Cabozantinib with Lu-177 DOTATATE administration IV

PHASE: 1b

STATUS: Recruiting

SPONSORS: Providence Health & Services

COLLABORATORS: Advanced Accelerator Applications SA & Exelixis

Dr. Kennecke discusses Cabozantinib with Lu-177 DOTATATE

DESCRIPTION:

The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.

READ:

2023 NANETS Abstract, 10/12/2023

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

PRINCIPAL INVESTIGATOR: 

Hagen Kennecke, MD, MHA

Providence Health & Services

CONTACT:

Mary McCormick, RN

EMAIL: mary.mccormick@providence.org

PHONE: 503-215-9570